DONGGUAN, China, Aug 5, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic antibodies and fusion proteins, is delighted to announce the completion of the first patient enrollment in China for its Phase I clinical trial of FP008 , a first-in-class immunotherapy for...
Hence then, the article about fapon biopharma announces the enrollment of the first patient in the phase i clinical trial of fp008 a first in class immunotherapy for solid tumors was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Fapon Biopharma Announces the enrollment of the First Patient in the Phase I Clinical Trial of FP008, A First-in-Class Immunotherapy for Solid Tumors )
Also on site :
- Police respond to incident at property in Dudley as residents 'spot armed police' in street
- Sinkhole on East Franklin Street Closes Lanes; Chapel Hill Urges for Detours
- Fire crews and Hazmat teams responded to fire involving lithium ion batteries at Higuera Street facility